Real-time enrollment status for this platinum-sensitive relapsed epithelial ovarian cancer clinical trial
Current Status
Recruiting
Checked: October 16, 2026 at 9:44 PM UTC
| NCT Number | NCT07816666 |
| Recruiting Status | Recruiting |
| Condition | Platinum-sensitive Relapsed Epithelial Ovarian Cancer |
| Phase | PHASE3 |
| Target Enrollment | 600 participants |
| Active Locations | 26 sites in the US |
| Sponsor | AstraZeneca |
| Last Updated on CT.gov | October 16, 2026 (21 hours ago) |
As of October 16, 2026: Clinical trial NCT07816666 is currently recruiting participants. This phase3 study for platinum-sensitive relapsed epithelial ovarian cancer is actively seeking new participants at 26 locations across the United States. The study is sponsored by AstraZeneca. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07816666 is actively recruiting participants as of October 16, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 26 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07816666 was last updated 21 hours ago (October 16, 2026). HelloStudys verifies this status automatically.